Skip to main content

Sarepta Therapeutics Value Stock - Dividend - Research Selection

Sarepta Therapeutics

ISIN: US8036071004, WKN: A1J1BH

Market price date: 11.01.2021
Market price: 89,76 USD




Sarepta Therapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2020
Cash flow
Net operating cash flow -456.463.000
Capital Expenditures -62.713.000
Free cash flow -519.176.000
Balance sheet
Total Equity 818.187.000
Liabilities & Shareholders equity 1.822.820.000
Income statement
Net income -715.075.000
Eps (diluted) -9,710
Diluted shares outstanding 73.615.000
Net sales/revenue 380.833.000

Fundamental ratios calculated on: 11-01-2021

Ratios
Key figures 11-01-2021
Cash flow
P/C -14,48
   
P/FC -12,73
Balance sheet
ROI-39,23
ROE44,89
Income statement
P/E-9,24
Div. Yield0,00%
P/B8,08
P/S17,35


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSRPT
Market Capitalization6.057.778.176,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split2012-07-12,1.0000/6.0000
Internetwww.sarepta.com


Description of the company

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children\'s Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit\'s utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.sarepta.com